ESTRO 2025 - Abstract Book

S1357

Clinical - Lung

ESTRO 2025

Conclusion: Adherence to guidelines was good, except for histological confirmation and pulmonary function tests. Toxicity/response were comparable to other studies, though our follow-up period was relatively short. In future, more precise methods of estimating dose accumulation, such as image registration, may improve confidence in patient selection.

Keywords: Reirradiation, radiotherapy

2471

Mini-Oral Conventional Radiotherapy and Thoracic SABR for Synchronous Oligometastatic NSCLC: Acute Toxicity Findings from the SARON Thoracic Safety Sub-Study Ragu Ratnakumaran 1,2 , Rushil Patel 3 , Nicholas Counsell 4 , Joanna Smith 4 , Ka Man Mak 4 , Gerard G Hanna 5 , John Conibear 6 , Kevin N Franks 7 , Philip Mayles 8 , Anthony Pope 9 , Corinne Faivre-Finn 10,11 , Merina Ahmed 1,2 , Sanjay Popat 1,12 , Shahreen Ahmad 13 , Qamar Ghafoor 14 , Charles Comins 15 , Crispin Hiley 16,17 , Martin Forster 18,17 , Alexander Martin 19 , Stephen Harrow 20,21 , Iain Phillips 20 , Andrew Bates 22 , Philip Atherton 23 , David Landau 13 , Fiona McDonald 1,2 1 The Lung Unit, Royal Marsden Hospital, London, United Kingdom. 2 Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom. 3 National Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, Northwood, United Kingdom. 4 CRUK & UCL Cancer Trials Centre, University College London, London, United Kingdom. 5 Discipline of Radiation Therapy, Trinity College, Dublin, Ireland. 6 Department of Radiotherapy, St. Bartholomews Hospital, London, United Kingdom. 7 Department of Clinical Oncology, Leeds Cancer Centres NHS Trust, Leeds, United Kingdom. 8 Department of Physics, University of Liverpool, Liverpool, United Kingdom. 9 Department of Radiotherapy, The Clatterbridge Cancer Centre, Liverpool, United Kingdom. 10 Department